[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"interstitial-lung-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:interstitial-lung-disease":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,87,0,25,[9,50,78,92,120,144,169,201,214,240,267,290,314,334,366,392,413,435,455,485,505,532,556,586,609],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":34,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100053350","phase-3-fibrotic-disease-activity-in-cardiopulmonary-disorders-using-18f-fibroblast-activation-protein-inhibitor-18f-fapi-74-petct-imaging-100053350",false,"NCT07613099","Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET\u002FCT Imaging","Evaluation of Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74 PET\u002FCT Imaging)","* INCLUSION CRITERIA\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Provision of signed and dated informed consent form\n2. Stated willingness to comply with all study procedures and availability for the duration of the study\n3. Participant \\>=18 years old\n4. Has a specific diagnosis of a cardiopulmonary and\u002For vascular disease that puts them at risk of developing or having developed tissue fibrosis.\n5. Has undergone prior imaging of lungs, heart, and\u002For vasculature with chest CT\n6. Able to lie on the PET\u002FCT scanner for imaging up to 45 minutes.\n7. For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 4 weeks after the end of FAPI-PET\u002FCT or the FDG PET\u002FCT scan.\n8. For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner during study participation and for an additional 4 weeks after the end of FAPI-PET\u002FCT or the FDG PET\u002FCT scan.\n9. Ability of subject to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. History of allergic reactions attributed to compounds of similar chemical or biologic composition to 18F-FAPI-74 or other agents used in the study.\n2. Uncontrolled intercurrent illness, factors, or social situations that would limit compliance with study requirements\n3. Pregnancy or lactation\n4. Women able to become pregnant or men actively trying to father a child and are unwilling to use an effective form of birth control during the study and 4 weeks after the last 18F-FAPI-74 PET\u002FCT scan or the FDG PET\u002FCT scan.\n5. Subjects with severe claustrophobia unresponsive to oral anxiolytics.\n6. Subjects weighing \\> 350 lbs (weight limit for PET scanner table), or unable to fit within the imaging gantry","ALL","18 Years","100 Years",{"count":21,"type":22},210,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","Background:\n\nInjury or diseases of the heart and lung can sometimes cause scar tissue (fibrosis) to build up in those organs. Current imaging scans can see this scar tissue once it has formed, but researchers want to find a way to detect the fibrosis in its earliest stages, while there might still be time to prevent serious damage. A new tracer (a radioactive substance injected during imaging scans) may be able to help.\n\nObjective:\n\nTo test a new tracer (18F-FAPI-74) during imaging scans in people with heart or lung disease.\n\nEligibility:\n\nPeople aged 18 years and older with lung or heart disease that may cause scarring in those organs.\n\nDesign:\n\nParticipants will have 6 clinic visits over 2 years.\n\nParticipants will be screened: They will have blood tests and tests of their heart and lung function. Those with heart disease will have a magnetic resonance imaging (MRI) scan of the heart.\n\nThe study tracer will be used with positron emission tomography (PET)\u002Fcomputed tomography (CT) scans. The study tracer will be injected into a vein in the arm. Participants will lie on a padded bed that slides through a donut-shaped machine.\n\nParticipants will have scans with the study tracer 2 times, 8 to 12 months apart. They will also have standard CT scans and blood tests during these visits. They will also have blood tests at 3 and 6 months between these visits.\n\nParticipants will have a follow-up visit after 18 to 24 months. The study scans, MRI and standard CT scans, and lung function tests may be repeated....",[28,29,30,31,32,33],"Allogeneic Stem Cell Transplantation","Lung Allograft Transplantation","Interstitial Lung Disease","Acute Lung Injury","Pulmonary Arterial Hypertension","Cardiovascular Diseases",[35,36],"Fibroblast activation protein (FAP) FAPI\u002FPET","Fibrotic Disease Activity","NOT_YET_RECRUITING","2026-07-10",{"date":40,"type":41},"2026-07-13","ACTUAL",{"date":43,"type":22},"2026-07-16",{"date":45,"type":22},"2033-05-26",{"name":47,"class":48},"National Heart, Lung, and Blood Institute (NHLBI)","NIH",1,{"id":51,"slug":52,"hasResults":12,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":77},"100053910","phase-3-study-of-the-efficacy-and-safety-of-inhaled-treprostinil-in-subjects-with-progressive-pulmonary-fibrosis-teton-ppf-100053910","NCT05943535","Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)","A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)","Inclusion Criteria:\n\n1. Subject gives voluntary informed consent to participate in the study.\n2. Subject is ≥18 years of age, inclusive, at the time of signing informed consent.\n3. Subject has radiological evidence of pulmonary fibrosis of \\>10% extent on an HRCT scan in the previous 12 months (confirmed by central review).\n4. Subject has a diagnosis of PPF (other than IPF) that fulfills at least 1 of the following criteria for progression within 24 months of screening despite standard treatment of ILD, as assessed by the Investigator:\n\n   1. Clinically significant decline in % predicted FVC based on ≥10% relative decline\n   2. Marginal decline in % predicted FVC based on ≥5% to \\\u003C10% relative decline combined with worsening of respiratory symptoms\n   3. Marginal decline in % predicted FVC based on ≥5% to \\\u003C10% relative decline combined with increasing extent of fibrotic changes on chest imaging\n   4. Worsening of respiratory symptoms as well as increasing extent of fibrotic changes on chest imaging\n5. FVC ≥45% predicted at Screening (confirmed by central review).\n6. Subjects must be on 1 of the following:\n\n   1. On nintedanib or pirfenidone for ≥90 days prior to Baseline and in the Investigator's opinion, are planning to continue treatment through the study\n   2. Not on treatment with nintedanib or pirfenidone for ≥90 days prior to Baseline and in the Investigator's opinion, not planning to initiate either treatment during the study.\n\n   Concomitant use of both nintedanib and pirfenidone is not permitted.\n7. Subjects treated with immunosuppressive agents (eg, mycophenolate, methotrexate, azathioprine, oral corticosteroids, rituximab) need to be on treatment for at least 120 days prior to Baseline and, in the Investigator's clinical opinion, must be refractory to treatment.\n8. Women of childbearing potential must be non-pregnant (as confirmed by a urine pregnancy test at Screening and Baseline) and non-lactating, and will agree to do 1 of the following:\n\n   1. Abstain from intercourse (when it is in line with their preferred and usual lifestyle)\n   2. Use 2 medically acceptable, highly effective forms of contraception for the duration of the study, and at least 30 days after discontinuing study drug.\n\n   i. Medically acceptable, highly effective forms of contraception can include approved hormonal contraceptives (oral, injectable, and implantable) and barrier methods (such as a condom or diaphragm) when used with a spermicide.\n\n   Women who are successfully sterilized (including hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or postmenopausal (defined as amenorrhea for at least 12 consecutive months) are not considered to be of reproductive potential.\n9. Males with a partner of childbearing potential must agree to use a condom for the duration of treatment and for at least 48 hours after discontinuing study drug.\n10. In the opinion of the Investigator, the subject is able to communicate effectively with study personnel, and is considered reliable, willing, and likely to be cooperative with protocol requirements, including attending all study visits.\n\nExclusion Criteria:\n\n1. Subject is pregnant or lactating.\n2. Subject has primary obstructive airway physiology (forced expiratory volume in 1 second\u002FFVC \\\u003C0.70 at Screening) or greater extent of emphysema than fibrosis on HRCT (confirmed by central review).\n3. Subject has a diagnosis of IPF.\n4. Subject has shown intolerance or significant lack of efficacy to a prostacyclin or prostacyclin analogue that resulted in discontinuation or inability to effectively titrate that therapy.\n5. Subject has received any PAH-approved therapy, including prostacyclin therapy (epoprostenol, treprostinil, iloprost, or beraprost; except for acute vasoreactivity testing), IP receptor agonists (selexipag), endothelin receptor antagonists, phosphodiesterase type 5 inhibitors (PDE5-Is), soluble guanylate cyclase stimulators, or activin signaling inhibitors (sotatercept) within 60 days prior to Baseline. As needed use of a PDE5-I for erectile dysfunction is permitted, provided no doses are taken within 48 hours prior to any study-related efficacy assessments.\n6. Subject is receiving \\>10 L\u002Fmin of oxygen supplementation by any mode of delivery at rest at Baseline.\n7. Exacerbation of ILD or active pulmonary or upper respiratory infection within 30 days prior to Baseline. Subjects must have completed any antibiotic or steroid regimens for treatment of the infection or acute exacerbation more than 30 days prior to Baseline to be eligible. If hospitalized for an acute exacerbation of ILD or a pulmonary or upper respiratory infection, subjects must have been discharged more than 90 days prior to Baseline to be eligible.\n8. Subject has uncontrolled cardiac disease, defined as myocardial infarction within 6 months prior to Baseline or unstable angina within 30 days prior to Baseline.\n9. Use of any other investigational drug\u002Fdevice or participation in any investigational study in which the subject received a medical intervention (ie, procedure, device, medication\u002Fsupplement) within 30 days prior to Screening. Subjects participating in non-interventional, observational, or registry studies are eligible.\n10. Acute pulmonary embolism within 90 days prior to Baseline.\n11. In the opinion of the Investigator, the subject has any condition that would interfere with the interpretation of study assessments or would impair study participation or cooperation.\n12. In the opinion of the Investigator, life expectancy \\\u003C12 months due to ILD or a concomitant illness.\n13. Subject has received nerandomilast within 60 days prior to Baseline.",{"count":58,"type":22},698,[25],"Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.",[62,30],"Progressive Pulmonary Fibrosis",[64,65,66],"Treprostinil","PPF","ILD","RECRUITING","2026-07-09",{"date":40,"type":41},{"date":71,"type":41},"2023-10-30",{"date":73,"type":22},"2027-11",{"name":75,"class":76},"United Therapeutics","INDUSTRY",165,{"id":79,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":81,"briefSummary":82,"conditions":83,"keywords":84,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":91,"locationsCount":49},"100641631",{"count":21,"type":22},[25],"Background:\n\nInjury or diseases of the heart and lung can sometimes cause scar tissue (fibrosis) to build up in those organs. Current imaging scans can see this scar tissue once it has formed, but researchers want to find a way to detect the fibrosis in its earliest stages, while there might still be time to prevent serious damage. A new tracer (a radioactive substance injected during imaging scans) may be able to help.\n\nObjective:\n\nTo test a new tracer (18F-FAPI-74) during imaging scans in people with heart or lung disease.\n\nEligibility:\n\nPeople aged 18 years and older with lung or heart disease that may cause scarring in those organs.\n\nDesign:\n\nParticipants will have 6 clinic visits over 2 years.\n\nParticipants will be screened: They will have blood tests and tests of their heart and lung function. Those with heart disease will have a magnetic resonance imaging (MRI) scan of the heart.\n\nThe study tracer will be used with positron emission tomography (PET)\u002Fcomputed tomography (CT) scans. The study tracer will be injected into a vein in the arm. Participants will lie on a padded bed that slides through a donut-shaped machine.\n\nParticipants will have scans with the study tracer 2 times, 8 to 12 months apart. They will also have standard CT scans and blood tests during these visits. They will also have blood tests at 3 and 6 months between these visits.\n\nParticipants will have a follow-up visit after 18 to 24 months. The study scans, MRI and standard CT scans, and lung function tests may be repeated.",[28,29,30,31,32,33],[35,36],"2026-07-01",{"date":87,"type":41},"2026-07-02",{"date":89,"type":22},"2026-07-07",{"date":45,"type":22},{"name":47,"class":48},{"id":93,"slug":94,"hasResults":12,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":99,"targetDuration":4,"studyType":23,"phases":101,"briefSummary":103,"conditions":104,"keywords":107,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":49},"100541118","phase-2-h01-in-adults-with-interstitial-lung-disease-the-solis-study-100541118","NCT06325696","H01 in Adults With Interstitial Lung Disease (The SOLIS Study)","Phase IIa Investigation of H01 in Adults With Interstitial Lung Disease (The SOLIS Study)","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Ability of subject to understand, and the willingness to sign a written informed consent document and comply with requirements of the study\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Male or Female participants ages \\>18 years\n* MD diagnosis of Idiopathic Pulmonary Fibrosis or other progressive ILD as defined previously\n* DLCO\\>30% and FVC\\>45%\n* Subjects in reproductive age who are heterosexually active must use an acceptable method of contraception: condoms (male or female) with or without a spermicidal agent, diaphragm or cervical cap with spermicide, IUD, or Hormone-based contraceptive\n* Agreement to adhere to Lifestyle Considerations throughout study duration\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Active on lung transplantation list\n* On supplemental oxygen at rest\n* Evidence of an acute respiratory infection or exacerbation of pulmonary fibrosis\n* Known diagnosis of celiac disease or wheat or gluten allergies\n* Cirrhosis or active viral or non-viral hepatitis: Bilirubin, AST and ALT values higher than twice the upper range of normal, or a Child-Pugh score of 7 or more\n* Subjects with history of active Inflammatory Bowel Disease, dysphagia, achalasia, or difficulty swallowing capsules, tablets or pills\n* Subjects with significant renal impairment defined as eGFR lower than 40 ml\u002Fmin.\n* Subjects with a baseline corrected Fridericia's QT interval (QTcF) \\>450ms or baseline ECG abnormalities which, in the opinion of the study physician, are clinically significant and would place the participant at increased risk for adverse effects.\n* Subjects with ongoing alcohol or illegal drug use disorder\n* Subjects who are pregnant, lactating or attempting to conceive\n\n  * Participants able to become pregnant (have not completed menopause, had a hysterectomy and\u002For both tubes and\u002For both ovaries removed) must use effective birth control methods to try and not become pregnant while participant in this study. Methods include (a) partner vasectomy, (b) bilateral tubal ligation, (c) intrauterine devices (IUDs), (d) hormonal implants (such as Implanon), or (e) other hormonal methods (birth control pills, injections, patches, vaginal rings).\n  * Male participants able to father children with a partner able to become pregnant must agree to use effective birth control (listed above) to participate in this study.\n* Known allergy to hymecromone or any component thereof\n* Chronic therapy with medications that are known potent human UDP-glucuronosyltransferase inhibitors: canagliflozin, temazepam, tacrolimus.\n* Physician concern that participant may not adhere to the study protocol\n* Current participation in another clinical treatment trial for ILD. May participate after 12 weeks from conclusion of another treatment trial.\n* Changing dose of other ILD medications over the 3 months prior to baseline\n* Any condition(s) or diagnosis, both physical or psychological, or physical exam finding that place the participant at increased risk for adverse effects, as determined by the study physician.",{"count":100,"type":22},37,[102],"PHASE2","Background:\n\nInterstitial lung disease affects the tissues that aid the transfer of oxygen and carbon dioxide between the air and the bloodstream. The disease can cause fibrosis, a thickening and scarring of lung tissue. Fibrosis often continues getting worse, and most people with this disease die in 3 to 5 years.\n\nObjective:\n\nTo test a study drug (hymecromone) in people with interstitial lung disease or lung fibrosis.\n\nEligibility:\n\nPeople aged 18 years and older with interstitial lung disease or lung fibrosis.\n\nDesign:\n\nParticipants will have at least 7 clinic visits over 5 months.\n\nParticipants will have screening and baseline visits. They will have blood tests and tests of their heart function. They will give a sputum sample. Other tests will include:\n\nSpirometry: Participants will breathe in and out through a mouthpiece to measure how much air they can hold in their lungs and how hard they can breathe.\n\nDiffusion capacity of lungs for carbon monoxide: Participants will breathe in a gas that contains a small amount of carbon monoxide. Then they will breathe through a mouthpiece. This test measures how well oxygen moves from the air into the blood.\n\nResting energy expenditure. Participants will lie still for 30 minutes with a clear dome over their head. This test measures the calories their body burns at rest.\n\n6-minute walk test. Participants will walk at their normal pace for 6 minutes. Their vital signs and blood oxygen levels will be checked.\n\nHymecromone is a tablet taken by mouth. Participants will take 2 tablets every morning and 2 tablets every night for 12 weeks. Tests will be repeated at study visits.",[30,105,106],"Idiopathic Pulmonary Fibrosis","Lung Diseases, Interstitial",[108,109,110,111],"Pulmonary Fibrosis","Lung disease","Hyaluronan","Drug","2026-06-30",{"date":85,"type":41},{"date":115,"type":41},"2025-05-05",{"date":117,"type":22},"2027-12-31",{"name":119,"class":48},"National Institute of Environmental Health Sciences (NIEHS)",{"id":121,"slug":122,"hasResults":12,"nctId":123,"briefTitle":124,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":127,"sex":17,"minAge":18,"maxAge":128,"enrollmentInfo":129,"targetDuration":4,"studyType":23,"phases":131,"briefSummary":133,"conditions":134,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":49},"100553634","pilot-study-of-nitrate-rich-beetroot-juice-supplementation-in-patients-with-idiopathic-pulmonary-fibrosis-ipf-100553634","NCT06488638","Pilot Study of Nitrate-rich Beetroot Juice Supplementation in Patients With Idiopathic Pulmonary Fibrosis (IPF)","BEET-IPF","IPF Patients: Inclusion Criteria\n\n1. Patients aged 18-85 years with a prior specialist multidisciplinary team diagnosis of idiopathic pulmonary fibrosis (IPF) based on current established consensus guidelines.\n2. Medical Research Council (MRC) breathlessness grade 1-3\n3. Judged clinically stable for 3 months prior to recruitment by the investigator.\n\nIPF Patients: Exclusion Criteria\n\n1. Baseline spirometry with FEV1\u002FFVC ratio \\\u003C 0.7.\n2. Neoplastic disease undergoing treatment or active follow up.\n3. Presence of infection or exacerbation requiring hospitalization, within last 3 months.\n4. Current tobacco smoker or use of nicotine containing vapes (within 3 months)\n5. Current use of ambulatory or long-term oxygen therapy (LTOT).\n6. Peripheral oxygen saturations \\\u003C85% during 6-minute walk-test.\n7. Any condition which would prevent completion of cycle-ergometer testing, pulmonary function testing (PFT) or 6-minute walk testing as judged by the investigator.\n8. Participation in a pulmonary rehabilitation (PR) program in the last 3 months.\n9. Any condition excluding CPET based on the absolute contraindication as the ACCP\u002FATS guidelines 2003\n10. Positive pregnancy test in females of childbearing age.\n11. Symptomatic peripheral vascular disease\n12. Concomitant use of nitrate-based medicine or phosphodiesterase V inhibitors\n\nControls: Inclusion Criteria\n\n1\\) Age and sex-matched to participants in the IPF cohort. Note: the participants will be age-matched within a 5-year age bracket.\n\nControls: Exclusion Criteria\n\n1. Inability to give informed written consent.\n2. Malignancy (except localised squamous or basal cell skin carcinoma) undergoing active investigation, treatment, or follow-up.\n3. Significant cardiorespiratory disease as judged by the investigator.\n4. Diabetes mellitus requiring treatment with pharmacology therapy.\n5. Current tobacco smoker or use of nicotine containing vapes (within three months).\n6. Symptomatic peripheral vascular disease.\n7. Concomitant use of nitrate-based medicine or phosphodiesterase V inhibitors.",true,"85 Years",{"count":130,"type":22},16,[132],"NA","Idiopathic pulmonary fibrosis (IPF) is a type of scarring (fibrotic) lung disease. Reduced exercise capacity is a key symptom experienced by patients. In previous research the investigators identified that an interval-based exercise programme led to significant improvements in exercise capacity (Wallis et al Antioxidants. 2023).\n\nAn unexpected finding was that in patients with IPF, exercise led to a reduction in blood nitrite concentrations an observation the investigators did not see in non-affected individuals. Research has identified that nitrite concentrations are expected to increase after exercise and the size of this increase is related to an individual's exercise capacity. There is also evidence from healthy individuals and patients with chronic obstructive pulmonary disease (COPD) that nitrate supplementation (a source of nitrite) improves response to exercise training. However, in both these groups an exercise-induced fall in blood nitrite concentrations has not been observed. Hence our finding of an exercise-induced fall in blood nitrite levels in IPF patients suggest that they may be especially sensitive to supplementation with nitrate, commercially available as nitrate-rich beetroot juice (NRBJ).\n\nThis current study investigates this in a pilot placebo-controlled, double-blind, randomised, cross-over study of NRBJ on exercise capacity in IPF patients.\n\nAims In patients with IPF\n\n* Quantify the effect of nitrate supplementation on exercise capacity\n* Determine the effect of nitrate supplementation on blood markers of nitric oxide production\u002Fmetabolism.\n* Determine the effect of nitrate supplementation on forearm blood flow. Sample size: n=8 IPF patients, aged 18-85years and medical research breathlessness scale 1-3 Intervention: 3-days (two-times daily) NRBJ or nitrate-depleted placebo juice (both commercially available) with subsequent constant-load exercise test (Primary outcome). Following at least 1 week wash-out period participants will cross-over and repeat.\n\nA cohort (n=8) of age, sex-matched controls without IPF will be enrolled for comparison of forearm blood flow and pre-exercise venous blood samples for biomarkers comparison only.\n\nNumber of sites: 1",[105,30],"2026-06-26",{"date":112,"type":41},{"date":138,"type":41},"2026-02-13",{"date":140,"type":22},"2027-06-03",{"name":142,"class":143},"University Hospital Southampton NHS Foundation Trust","OTHER",{"id":145,"slug":146,"hasResults":12,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":152,"enrollmentInfo":153,"targetDuration":155,"studyType":156,"phases":4,"briefSummary":157,"conditions":158,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":168},"100526015","an-open-label-prospective-multicenter-study-to-evaluate-safety-and-tolerability-of-dry-powder-inhaled-treprostinil-in-ph-100526015","NCT06129240","An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH","An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in Pulmonary Hypertension","ASCENT","Cohort A Key Inclusion Criteria:\n\n1. Males or Females between 18 years to 80 years of age.\n2. Has a confirmed diagnosis of WHO Group 3 PH-ILD based on CT chest imaging performed, which demonstrates evidence of diffuse parenchymal lung disease and FEV1\u002FFVC (absolute values) ≥ 70% and are required to have evidence of pulmonary hypertension (PH) as demonstrated from right heart catheterization (RHC) with the following hemodynamic parameters.\n\n   1. i) Pulmonary vascular resistance (PVR) ≥ 3 Wood Units (WU) and ii) Pulmonary capillary wedge pressure (PCWP) of ≤ 15 mmHg and iii) A mean pulmonary arterial pressure (mPAP) of ≥ 30 mmHg.\n\n      OR\n   2. An exploratory subset of subjects with ILD: i) Pulmonary vascular resistance (PVR) ≥ 3 Wood Units (WU) and ii) Pulmonary capillary wedge pressure (PCWP) of ≤ 15 mmHg and iii) A mean pulmonary arterial pressure (mPAP) of ≥ 21 mmHg.\n3. 6-minute walk distance of ≥ 125 meters\n\nCohort A Key Exclusion Criteria:\n\nA Subject is not eligible for inclusion in the study if any of the following criteria apply:\n\n1. PH in the Updated WHO Classification Groups 1, 2, 4, or 5.\n2. History of hemodynamically significant left-sided heart disease.\n3. Exacerbation of underlying lung disease or active pulmonary or upper respiratory infections.\n4. Initiation of pulmonary rehabilitation.\n\nCohort B Key Inclusion Criteria\n\n1. Male or Females between 18 years to 75 years of age at Screening.\n2. Has a diagnosis of WHO Group 3 PH-ILD confirmed with CT chest imaging performed at the screening visit, which demonstrates evidence of diffuse parenchymal lung disease and FEV1\u002FFVC (absolute values) ≥70%. Subjects are required to have evidence of pulmonary hypertension (PH) as demonstrated from right heart catheterization (RHC) with the following documented parameters:\n\n   1. Pulmonary vascular resistance (PVR) ≥3 Wood Units (WU) and\n   2. Pulmonary capillary wedge pressure (PCWP) of ≤ 15 mmHg and\n   3. A mean pulmonary arterial pressure (mPAP) of ≥ 25 mmHg\n3. Subjects must be on protocol specified dose of inhaled treprostinil QID not at treatment goal, and able to transition from their prescribed dose of inhaled Treprostinil therapy to LIQ861.\n4. 6-minute walk distance of ≥ 200 meters\n\nCohort B Key Exclusion Criteria\n\n1. PH in the Updated WHO Classification Groups 1, 2, 4, or 5.\n2. Inability to titrate inhaled treprostinil above 5 breaths (Tyvaso®) or above 16 mcg Tyvaso DPI®.\n3. History of Bronchospasm with Tyvaso or Tyvaso DPI.\n4. History of persistent moderate asthma or severe asthma.\n5. History of hemodynamically significant left-sided heart disease.\n6. Exacerbation of underlying lung disease or active pulmonary or upper respiratory infections.","80 Years",{"count":154,"type":22},80,"52 Weeks","OBSERVATIONAL","Study LTI-401 is an open-label, multicenter study which will evaluate the safety and tolerability of LIQ861 in subjects who have WHO Group 1 \\& 3 PH.",[159,30],"Pulmonary Hypertension","2026-06-24",{"date":135,"type":41},{"date":163,"type":41},"2023-12-28",{"date":165,"type":22},"2028-02-08",{"name":167,"class":76},"Liquidia Technologies, Inc.",23,{"id":170,"slug":171,"hasResults":12,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":23,"phases":178,"briefSummary":179,"conditions":180,"keywords":184,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":200},"100627695","effects-of-oxygen-supplementation-during-the-6-minute-walk-test-in-chronic-respiratory-failure-or-exertional-hypoxemia-100627695","NCT07451977","Effects of Oxygen Supplementation During the 6-Minute Walk Test in Chronic Respiratory Failure or Exertional Hypoxemia","Evaluation of the Effects of the Oxygen Supplementation During 6-minute Walking Test in Patients With Chronic Respiratory Failure or Exertional Hypoxiemia","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Diagnosis of chronic respiratory disease admitted for pulmonary rehabilitation\n* One of the following conditions at discharge:\n* Chronic obstructive pulmonary disease with exertional hypoxemia\n* Chronic obstructive pulmonary disease with chronic respiratory failure requiring long-term oxygen therapy\n* Interstitial lung disease with chronic respiratory failure requiring long-term oxygen therapy\n* Clinically stable condition for at least one month\n* Optimized medical therapy during hospitalization\n* Ability to perform the 6-minute walk test\n* Signed informed consent\n\nExclusion Criteria:\n\n* Lung diseases other than chronic obstructive pulmonary disease or interstitial lung disease\n* Resting oxygen flow requirement greater than 4 liters per minute\n* Orthopedic, neurological, or cognitive conditions that may limit walking performance\n* Recent cardiovascular or cerebrovascular events within the previous 3 months",{"count":177,"type":22},114,[132],"The aim of this multicenter crossover trial is to describe the effect of adding a therapeutic dose of exertional oxygen therapy, in terms of exercise performance, gas exchange, heart rate, symptoms perception and subjective easiness of performance, in a cohort of subjects hospitalized in specialized pulmonary rehabilitation centers with a diagnosis of chronic respiratory failure and\u002For exertional hypoxemia due to chronic obstructive pulmonary disease or interstitial lung disease.\n\nResearchers will compare the walking performance during 6-minute walk test performed with the liters of oxygen administered as prescribed at rest (for patients with chronic respiratory failure) or in room air (for patients with exertional hypoxemia only), to the performance during a 6-minute walk test performed with the double the flow rate prescribed at rest, or with 2 L\u002Fmin for patients with exertional hypoxemia only. The two tests will be performed in random order, at least 3 hours apart and no later than 24 hours apart from each other.\n\nThe main outcome will be the difference between the distance walked in the two 6-minute walk test in the two conditions. Furthermore, will be also collected and compared: the oxygen saturation and heart rate every minute, the initial and final dyspnea and fatigue, as assessed by Borg scale, and the easiness of performance through a dedicated questionnaire. The estimated sample size will be 114 patients.\n\nThis study will provide some basis for a more accurate prescription of exercise-related oxygen therapy, offering insights into the phenotype of patients who may derive the greatest benefit from this intervention. It will also stimulate discussion regarding the optimal timing and dosing of oxygen administration during exertion in patients with respiratory failure.",[181,182,183,30],"Chronic Respiratory Failure","Hypoxemia","Chronic Obstructive Pulmonary Disease (COPD)",[185,186,187,188,189,190],"oxygen supplementation","6-minute walk test","chronic respiratory failure","exertional hypoxemia","pulmonary rehabilitation","exercise tolerance","2026-06-19",{"date":193,"type":41},"2026-06-23",{"date":195,"type":41},"2026-04-02",{"date":197,"type":22},"2028-09-30",{"name":199,"class":143},"Istituti Clinici Scientifici Maugeri SpA",6,{"id":202,"slug":4,"hasResults":12,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":203,"targetDuration":4,"studyType":23,"phases":204,"briefSummary":60,"conditions":205,"keywords":206,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":211,"leadSponsor":212,"locationsCount":213},"100511753",{"count":58,"type":22},[25],[62,30],[64,65,66],"2026-06-17",{"date":209,"type":41},"2026-06-18",{"date":71,"type":41},{"date":73,"type":22},{"name":75,"class":76},160,{"id":215,"slug":216,"hasResults":12,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":221,"targetDuration":4,"studyType":23,"phases":223,"briefSummary":224,"conditions":225,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":49},"100630376","phase-2-emapalumab-mda5-rapidly-progressive-interstitial-lung-disease-rp-ild-study-100630376","NCT07486869","Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study","Emapalumab for the Treatment of Anti-MDA5 Antibody Positive Rapidly Progressive Interstitial Lung Disease","Inclusion Criteria:\n\n* Progressive interstitial lung disease as determined by at least 2\u002F4 of the following:\n\n  1. worsening respiratory symptoms;\n  2. worsening or new oxygen requirement;\n  3. worsening disease on CT chest;\n  4. worsening Forced Vital Capacity (FVC1) or Diffusing Capacity for Carbon Monoxide (DLCO) on pulmonary function tests\n* MDA5 antibodies present\n* Elevated ferritin above the upper limit of normal (ULN)\n* Participant at least 18 years old\n\nExclusion Criteria:\n\n* Active, untreated bacterial, mycobacterial or fungal infection\n* Active herpes zoster infection\n* Currently requiring extracorporeal membrane oxygenation (ECMO)\n* Participant refusal to participate in the study\n* Pregnant women\n* Prisoners",{"count":222,"type":22},5,[102],"This is a proof of concept study to determine if Emapalumab appears effective for the treatment of anti-MDA5 antibody positive rapidly progressive interstitial lung disease (MDA5 RP-ILD). Emapalumab is a medication that is currently used for a severe problem with the immune system, called macrophage activation syndrome, and this disease shares some similar features with MDA5 RP-ILD.",[226,227,228,229,230,30,231],"Dermatomyositis","Dermatomyositis Sine Myositis","Dermatomyositis With Myopathy","Dermatomyositis With Respiratory Involvement","Dermatomyositis With Organ Involvement","Interstitial Lung Disease Due to Connective Tissue Disease (Disorder)","2026-06-16",{"date":209,"type":41},{"date":235,"type":22},"2026-07",{"date":237,"type":22},"2027-05",{"name":239,"class":143},"University of Miami",{"id":241,"slug":242,"hasResults":12,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":4,"eligibilityCriteria":246,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":128,"enrollmentInfo":247,"targetDuration":4,"studyType":23,"phases":249,"briefSummary":250,"conditions":251,"keywords":253,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":263,"leadSponsor":265,"locationsCount":49},"100632361","titrated-ambulatory-oxygen-in-fibrotic-ild-and-copd-with-isolated-exertional-hypoxemia-100632361","NCT07512687","Titrated Ambulatory Oxygen in Fibrotic ILD and COPD With Isolated Exertional Hypoxemia","Impact of Ambulatory Oxygen Delivery on Real-world Activity and Quality-of-life in Patients With Interstitial Lung Disease (ILD) and Chronic Obstructive Pulmonary Disease (COPD)","Inclusion Criteria:\n\n* Adults \\>= 18 years old and \\\u003C= 85 years old with fibrotic ILD or COPD able to provide informed consent\n* Fibrotic ILD includes idiopathic pulmonary fibrosis, sarcoidosis, or other ILD with fibrotic changes on lung imaging (reticulations, honeycombing, traction bronchiectasis)\n* COPD participants will have fixed airway obstruction on spirometry less than 70%-predicted as per Global Initiative for Obstructive Lung Disease (GOLD) diagnostic criteria\n* Participants will self-report as being ambulatory outside of home without use of assistance device such as a cane or walker\n* Stable lung disease on stable medical therapy for preceding 3 months\n* Isolated exertional hypoxemia (SpO2 less than 89% for \\>=10 seconds) on a 6MWT conducted while breathing room air\n* Able to maintain SpO2 \\>=89% for the full duration of a 6MWT while using the the POC and portable oxygen D-tank at POC setting of no higher than 6 and D-tank flow rate no higher than 6 liters per minute\n\nExclusion Criteria:\n\n* People \\\u003C18 years old or \\>85 years old\n* Participants with mixed ILD and COPD diagnoses\n* Resting hypoxemia less than 89% while breathing room air\n* Emergency room visit or hospital admission in 3 months prior to recruitment\n* Change in medical therapy in 3 months prior to recruitment\n* Need for ambulatory assistive device such as cane or walker\n* Pregnant\n* Currently smoking or residing with a current smoker\n* Currently engaged in a pulmonary rehabilitation program\n* Participants without a smartphone compatible with the Oxiwear app (necessary to collect Oxiwear oxygen saturation data) or those with a compatible smartphone but without home wifi or cellular service plan allowing for Oxiwear data uploading",{"count":248,"type":22},24,[132],"Fibrotic forms of interstitial lung disease (ILD) and chronic obstructive pulmonary disease (COPD) are chronic lung disease which often affect how well oxygen can get from the lungs into the blood. Low blood oxygen levels often leads to shortness of breath which can affect patients' activity levels and quality-of-life. Many people with fibrotic ILD and COPD only have low oxygen levels when they are walking or exercising. Oxygen that is only used for walking or exercise is called ambulatory oxygen therapy (AOT). Laboratory studies suggest that AOT improves shortness of breath and exercise ability. However, real-world studies of AOT have not shown similar results. AOT can be given to patients through different types of equipment, most commonly oxygen tanks or portable oxygen concentrators (POCs). While previous studies have suggested that AOT does not significantly improve patients' breathing or activity in the real-world, these studies most often gave all participants the same amount of oxygen with the same device. However, patients with ILD and COPD often have very different oxygen needs during exercise, and POCs and oxygen tanks are very different in how oxygen is administered.\n\nThis trial will test the feasibility of a study to determine whether real-world activity, symptoms, and quality-of-life are different with the use of different oxygen equipment when oxygen therapy has been adjusted to meet each participants' oxygen needs. A total of 24 participants (12 with fibrotic ILD and 12 with COPD) who only have low oxygen levels with activity will be randomly assigned to 2-week periods using either no oxygen therapy or oxygen delivered by oxygen tanks or POC. This trial will provide preliminary data to support a larger clinical trial to further test how different AOT equipment titrated to meet individual patients' needs may affect real-world outcomes in people with ILD and COPD.",[30,252,182],"Chronic Obstructive Pulmonary Disease",[254,255,256,257,258],"Ambulatory Oxygen Therapy","Portable Oxygen Concentrator","Exertional Hypoxemia","6-Minute Walk Test","Real-World Activity","2026-06-08",{"date":261,"type":41},"2026-06-11",{"date":235,"type":22},{"date":264,"type":22},"2027-10",{"name":266,"class":143},"State University of New York at Buffalo",{"id":268,"slug":269,"hasResults":12,"nctId":270,"briefTitle":271,"officialTitle":271,"acronym":4,"eligibilityCriteria":272,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":273,"targetDuration":4,"studyType":156,"phases":4,"briefSummary":275,"conditions":276,"keywords":278,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":282,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":289},"100545937","decipher-ild-a-real-world-patient-registry-in-group-3-pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-100545937","NCT06388421","DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)","Inclusion Criteria:\n\n1. Adults aged 18 years or older\n2. Diagnosis of fibrotic ILD based on high-resolution computed tomography imaging, including but not limited to:\n\n   1. Idiopathic interstitial pneumonia, including idiopathic pulmonary fibrosis\n   2. Autoimmune ILD\n   3. Chronic hypersensitivity pneumonitis\n   4. Nonspecific interstitial pneumonia\n   5. Occupational lung disease\n   6. Combined pulmonary fibrosis and emphysema with fibrosis greater than the extent of emphysema on lung imaging as determined by the Investigator\n3. For patients to be eligible for Cohorts 1 to 3: RHC confirmed PH (mean pulmonary artery pressure \\>20 mmHg, pulmonary artery wedge pressure\n\n   ≤15 mmHg, pulmonary vascular resistance \\>2 WU).\n4. For patients to be eligible for Cohort 1, they must not be receiving inhaled treprostinil at Baseline.\n5. For patients to be eligible for Cohort 2, they must have initiated\n\nTyvaso\u002FTyvaso DPI at 1 of the following time points:\n\n1. Baseline\n2. ≤90 days prior to Baseline 6. For patients to be eligible for Cohort 3, they must be receiving Tyvaso\u002FTyvaso DPI at Baseline and for \\>90 days prior to Baseline. 7. For patients to be eligible for Cohort 4: Prior RHC not meeting the definition of PH as described in Inclusion Criterion 3 but has a pulmonary artery wedge pressure ≤15 mmHg. 8. Co-enrollment in other observational or interventional studies is permitted. 9. Patient is willing and able to provide informed consent and complete surveys\u002Fquestionnaires in English or Spanish.\n\nExclusion Criteria:\n\n1. Confirmed diagnosis of Group 1, 2, 4, or 5 PH\n\n   a. In cases in which a patient has a diagnosis of PH-ILD along with a concomitant diagnosis of another PH group (eg, Group 1), enrollment may be permitted at the Investigator's discretion if, in their clinical judgment, PH-ILD is the predominant driver of the patient's PH.\n2. Confirmed diagnosis of Group 3 PH associated with lung diseases and or hypoxia other than fibrotic ILD, as outlined in Inclusion Criterion 2.\n3. Patients receiving inhaled treprostinil (Yutrepia™) at Baseline. Patients receiving other forms of PH therapy will be eligible for enrollment.",{"count":274,"type":22},900,"This is a prospective, real world, multicenter, registry of patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) and interstitial lung disease (ILD).",[277,159,30],"Pulmonary Hypertension Due to Lung Diseases and Hypoxia",[279,280,281],"pulmonary hypertension","interstitial lung disease","pulmonary hypertension associated with interstitial lung disease",{"date":283,"type":41},"2026-06-10",{"date":285,"type":41},"2025-01-23",{"date":287,"type":22},"2030-11-30",{"name":75,"class":76},67,{"id":291,"slug":292,"hasResults":12,"nctId":293,"briefTitle":294,"officialTitle":295,"acronym":296,"eligibilityCriteria":297,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":298,"targetDuration":4,"studyType":23,"phases":300,"briefSummary":301,"conditions":302,"keywords":303,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":313},"100606732","phase-3-efficacy-and-safety-study-of-treprostinil-palmitil-inhalation-powder-tpip-in-participants-with-pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-100606732","NCT07179380","Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)","A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease","PALM-ILD","Inclusion Criteria\n\n* Diagnosis of PH World Health Organisation (WHO) Group 3 associated with ILD \\[including but not limited to idiopathic interstitial pneumonia (IIP), chronic hypersensitivity pneumonitis (HSP), connective tissue disease-associated interstitial lung disease (CTD-ILD), combined pulmonary fibrosis and emphysema (CPFE)\\].\n* Confirmation of fibrotic interstitial lung disease by centrally overread computed tomography (CT) scan performed at Screening or within prior 12 months.\n* PH confirmed by right heart catheterization (RHC) at Screening or within 12 months prior to Screening, with the following hemodynamic findings:\n\n  * Mean pulmonary arterial pressure (mPAP) \\>20 millimetre of mercury (mmHg) and\n  * Pulmonary capillary wedge pressure (PCWP) of ≤15 mmHg and\n  * Pulmonary vascular resistance (PVR) ≥4 wood units (WU).\n* 6 Minute walking distance (6MWD) ≥100 and ≤500 meters at two 6MWTs at Screening performed at least 4 hours apart, with the difference between the 2 distances ≤15%.\n* Participants receiving chronic medication for underlying disease (e.g., antifibrotic, immunomodulators, immunosuppressants, etc.) and\u002For phosphodiesterase 5 (PDE5) inhibitors, should be on this treatment for ≥90 days and on a stable dose for ≥30 days prior to Screening.\n* Capable of giving signed informed consent as described in Section 10.1.5 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.\n\nExclusion criteria\n\n* Diagnosis of Pulmonary Hypertension WHO Groups 1, 2, 4, or 5, or subtypes of PH WHO Group 3 other than interstitial lung disease.\n* Primary diagnosis of chronic obstructive pulmonary disease (COPD) and\u002For forced expiratory volume in 1 second (FEV1)\u002FFVC \\\u003C0.7 (based on screening or historical spirometry within the prior 6 months).\n* Clinically significant left heart disease:\n\n  * evidence of clinically significant left-sided valvular heart disease,\n  * left ventricular failure with left ventricular ejection fraction (LVEF) \\\u003C45%, or diagnosis of heart failure with preserved ejection fraction (HFpEF)\n  * echocardiography findings at Screening suggestive for postcapillary PH\n  * unstable ischemic heart disease\n  * unstable arrhythmia, including uncontrolled atrial fibrillation (rate-controlled arrhythmia or paroxysmal atrial fibrillation is allowed)\n* Evidence of chronic thromboembolic disease or recent (within 6 months of Screening) acute pulmonary embolism.\n* Known hypersensitivity or contraindication to treprostinil or TPIP or TPIP formulation excipients (e.g., mannitol, leucine).\n* Current use of cigarettes or e-cigarettes: An adult who has smoked at least 100 cigarettes in his or her lifetime and who currently smokes either every day or some days.\n* Current use of inhaled marijuana, recreational or medical (current use defined as used at least one or more times during the past 30 days prior to Screening) or expected use during the study.\n* Any other medical or psychological condition including relevant laboratory abnormalities at Screening that, in the opinion of the Investigator, suggest a new and\u002For insufficiently understood disease and\u002For may present an unreasonable risk to the study participant as a result of his\u002Fher participation in this clinical trial, may impede their ability complete the study or the study assessments or confound the outcomes of the trial.\n\nNote: Other protocol defined inclusion\u002Fexclusion criteria may apply.",{"count":299,"type":22},344,[25],"The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP versus placebo on exercise capacity in adults with PH-ILD.",[159,30],[279,280],"2026-05-26",{"date":306,"type":41},"2026-05-27",{"date":308,"type":41},"2026-01-07",{"date":310,"type":22},"2028-12-30",{"name":312,"class":76},"Insmed Incorporated",109,{"id":315,"slug":316,"hasResults":12,"nctId":317,"briefTitle":318,"officialTitle":319,"acronym":4,"eligibilityCriteria":320,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":321,"targetDuration":4,"studyType":23,"phases":322,"briefSummary":323,"conditions":324,"keywords":325,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":327,"lastUpdatePostDateStruct":328,"startDateStruct":329,"completionDateStruct":331,"leadSponsor":333,"locationsCount":4},"100610934","phase-3-an-open-label-extension-study-of-treprostinil-palmitil-inhalation-powder-tpip-in-participants-with-pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-100610934","NCT07234032","An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)","A Long-term Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder for Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease","Inclusion Criteria\n\n* Participants who have completed the lead-in PH-ILD TPIP Study INS1009-311 (NCT07179380).\n* Capable of giving signed informed consent that includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.\n* Agree not to participate in any other interventional trials or use investigational drugs or devices while participating in the INS1009-312 study.\n\nExclusion Criteria\n\n* Participants who experienced any adverse events (AEs) evaluated as causally related to TPIP by the Investigator in a lead-in study, which in the opinion of the Investigator, could pose an unreasonable risk of continued treatments for the participant.\n* Current use or expected need for pulmonary arterial hypertension (PAH)-approved therapy, including prostacyclin, prostacyclin analogues or other prostacyclin receptor agonists, endothelin receptor antagonists, and\u002For soluble guanylate cyclase stimulator, or any PH-ILD approved treprostinil therapy. Use of phosphodiesterase 5 inhibitors in line with applicable guidelines is allowed.\n* Diagnosis of Pulmonary Hypertension World Health Organisation (WHO) Groups 1, 2, 4, or 5, or subtypes of PH WHO Group 3 other than interstitial lung disease (including combined pulmonary fibrosis and emphysema).\n* Evidence of left ventricular failure, heart failure with preserved ejection fraction (HFpEF) or postcapillary PH.\n* Known hypersensitivity or contraindication to treprostinil or TPIP or TPIP formulation excipients (eg, mannitol, leucine).\n\nNote: Other protocol-defined inclusion\u002Fexclusion criteria may apply.",{"count":299,"type":22},[25],"The primary objective of this study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PH-ILD from Study INS1009-311 (NCT07179380).",[159,30],[326],"pulmonary hypertension, interstitial lung disease","2026-05-21",{"date":304,"type":41},{"date":330,"type":22},"2026-06-05",{"date":332,"type":22},"2031-01-22",{"name":312,"class":76},{"id":335,"slug":336,"hasResults":12,"nctId":337,"briefTitle":338,"officialTitle":339,"acronym":340,"eligibilityCriteria":341,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":342,"targetDuration":4,"studyType":23,"phases":343,"briefSummary":344,"conditions":345,"keywords":352,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":357,"lastUpdatePostDateStruct":358,"startDateStruct":360,"completionDateStruct":362,"leadSponsor":364,"locationsCount":49},"100521365","ultrasound-and-respiratory-physiological-signals-in-lung-diseases-100521365","NCT06068647","Ultrasound and Respiratory Physiological Signals in Lung Diseases","Synergistic Assessment of Ultrasound Data and Respiratory physiOlogical Signals in luNg Diseases","SAURON","Inclusion Criteria:\n\n* inpatients admitted to the hospital due to diffuse interstitial lung diseases during exacerbation OR infectious interstitial pneumonia not caused by SARS-CoV-2 OR acute exacerbation of chronic obstructive pulmonary disease.\n* Outpatients with pulmonary paraseptal and\u002For panlobular emphysema and\u002For chronic obstructive pulmonary disease during stable phase.\n* Patients able to give written informed consent.\n\nExclusion Criteria:\n\n* history of skin irritation, redness, itching or allergic cutaneous symptoms.\n* Allergic reactions to adhesives or hydrogels.\n* Family history of adhesive skin allergies.\n* Presence of severe skin conditions such as wounds, burns or on any damaged skin.\n* Presence of strong magnetic fields in the study setting.\n* Presence of electromagnetic disturbances or significant ionizing radiation sources which might lead to signal artifacts.\n* Use of external cardiac defibrillators.\n* Use of diaphragmatic pacers.\n* Use of extra cardiac stimulators.\n* Pregnancy.\n* Pediatric population.",{"count":7,"type":22},[132],"The use of lung ultrasound is instrumental in the evaluation of many chest pathologies and its ability to detect pleuro-pulmonary pathology is widely accepted.\n\nHowever, the use of ultrasound to explore the state of the peripheral lung parenchyma, when the organ is still aerated, is a relatively new application.\n\nHorizontal and vertical artifacts are separate and distinct artifacts that can be seen during ultrasound examination of the lungs. While the practical role of lung ultrasound artifacts is accepted to detect and monitor many conditions, further research is needed for the physical interpretation of ultrasound artifacts. These artifacts are diagnostic signs, but we don't fully understand their origin.\n\nThe artifactual information deriving from the surface acoustic interaction, beyond the pleural line, in the ultrasound images of the normally aerated and non-deflated lung, represents the final result of complex interactions of acoustic waves with a specific three-dimensional structure of the biological tissue. Thus, the umbrella term \"vertical artifacts\" oversimplifies many physical phenomena associated with a pathological pleural plane. There is growing evidence that vertical artifacts are caused by physiological and pathological changes in the superficial lung parenchyma.\n\nTherefore, the need emerges to explore the physical phenomena underlying the artifactual ultrasound information deriving from the surface acoustic interaction of ultrasound with the pleuro-pulmonary structures.",[30,346,347,252,348,349,350,351],"Interstitial Lung Diseases","Interstitial Pneumonia","Emphysema or COPD","Ultrasonography","Ultrasound Imaging","Ultrasound",[351,350,349,353,354,355,356],"Emphysema","Chronic obstructive pulmonary disease","Interstitial pneumonia","Interstitial lung disease","2026-05-19",{"date":359,"type":41},"2026-05-20",{"date":361,"type":41},"2023-03-22",{"date":363,"type":22},"2026-09-30",{"name":365,"class":143},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":367,"slug":368,"hasResults":12,"nctId":369,"briefTitle":370,"officialTitle":371,"acronym":4,"eligibilityCriteria":372,"healthyVolunteers":12,"sex":17,"minAge":373,"maxAge":4,"enrollmentInfo":374,"targetDuration":4,"studyType":23,"phases":376,"briefSummary":377,"conditions":378,"keywords":379,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":385,"completionDateStruct":387,"leadSponsor":389,"locationsCount":391},"100385533","effects-of-drinking-beetroot-juice-on-exercise-performance-in-patients-with-fibrotic-interstitial-lung-disease-100385533","NCT04299945","Effects of Drinking Beetroot Juice on Exercise Performance in Patients With Fibrotic Interstitial Lung Disease","The Effects of Dietary Nitrate Supplementation on Exercise Tolerance in Patients With Fibrotic Interstitial Lung Disease","Inclusion Criteria:\n\n* A multidisciplinary diagnosis of idiopathic pulmonary fibrosis (IPF), idiopathic fibrotic nonspecific interstitial pneumonia (NSIP), chronic hypersensitivity pneumonitis (HP), or unclassifiable ILD with a differential diagnosis that consists of the above diagnoses\n* Fibrosis on high resolution computed tomography (HRCT): honeycombing, reticulation, or traction bronchiectasis\n* Oxygen saturation ≥92% by pulse oximetry at rest while breathing room air\n* Clinically stable for the preceding 6 weeks\n* Can fluently read and write in English\n\nExclusion Criteria:\n\n* Contraindication to exercise testing (e.g. significant cardiovascular, musculoskeletal, neurological disease) (see Table 4 from ERS\u002FATS consensus statement)\n* Other significant pulmonary or extra-pulmonary disease that, based on clinical assessment, could impair exercise capacity and\u002For oxygenation\n* FVC \\\u003C50% or DLCO \\\u003C25%\n* Use of prednisone \\>10 mg\u002Fday for \\>2 weeks within 3 months of the first study visit\n* Cardiac pacemaker or any metal or electronics inside of the body","19 Years",{"count":375,"type":22},15,[132],"Exercise training as part of a structured pulmonary rehabilitation program is a key factor in improving quality of life and symptoms in people with interstitial lung disease (ILD). Optimal methods of exercise training are yet to be explored in ILD. Drinking beetroot juice, which is rich in nitrate, has been shown to improve exercise performance in a variety of groups, but its effects in ILD have not been tested. The purpose of this study is to determine if drinking nitrate-rich beetroot juice can improve exercise performance compared to drinking nitrate-free beetroot juice in people with ILD.",[30],[66,380,381,280],"Nitrates","exercise","2026-05-13",{"date":384,"type":41},"2026-05-18",{"date":386,"type":41},"2024-08-07",{"date":388,"type":22},"2026-12-31",{"name":390,"class":143},"University of British Columbia",2,{"id":393,"slug":394,"hasResults":12,"nctId":395,"briefTitle":396,"officialTitle":397,"acronym":4,"eligibilityCriteria":398,"healthyVolunteers":127,"sex":17,"minAge":399,"maxAge":152,"enrollmentInfo":400,"targetDuration":4,"studyType":23,"phases":402,"briefSummary":403,"conditions":404,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":408,"startDateStruct":410,"completionDateStruct":411,"leadSponsor":412,"locationsCount":49},"100347151","skeletal-muscle-function-in-interstitial-lung-disease-100347151","NCT03800017","Skeletal Muscle Function in Interstitial Lung Disease","Investigating the Role of Skeletal Muscle Dysfunction on Dyspnea and Exercise Intolerance in Interstitial Lung Disease","Inclusion Criteria for ILD Patients:\n\n* Age 40-80 years (inclusive)\n* A multidisciplinary diagnosis of idiopathic pulmonary fibrosis (IPF), idiopathic fibrotic nonspecific interstitial pneumonia (NSIP), chronic hypersensitivity pneumonitis (HP), or unclassifiable ILD with a differential diagnosis that consists of the above diagnoses\n* Fibrosis on high resolution computed tomography (HRCT): honeycombing, reticulation, or traction bronchiectasis\n* Appropriate candidate for pulmonary rehabilitation\n* 6 minute walk distance 50m or more\n* Oxygen saturation ≥ 92% by pulse oximetry at rest while breathing room air\n* Clinically stable for the preceding 6 weeks\n* Can fluently read and write in English\n\nInclusion Criteria for Healthy Controls:\n\n* Age 40-80 (inclusive)\n* Normal pulmonary function (80-120% predicted)\n* No lung or cardiovascular disease\n* Can fluently read and write in English\n\nExclusion Criteria for the ILD patients:\n\n* Contraindication to exercise testing (e.g. significant cardiovascular, musculoskeletal, neurological disease)\n* Other significant extra-pulmonary disease that, based on clinical assessment, could impair exercise capacity and\u002For oxygenation\n* Forced vital capacity (FVC) less than 50% or Diffusion capacity for carbon monoxide (DLCO) less than 25%\n* Concurrent or recent participation (less than 6 months) in a pulmonary rehabilitation program\n* Use of prednisone greater than 10 mg\u002Fday for more than 2 weeks within 3 months of the first study visit\n* Significant emphysema (less than 10% volume on HRCT or FEV1\u002FFVC less than 0.70)\n\nExclusion Criteria for Healthy Controls:\n\n* Currently smoking or previously smoked more than 10 pack-years\n* Any medical conditions that prevents them for exercising safely\n* Cardiac pacemaker or any metal or electronic inside the body","40 Years",{"count":401,"type":22},40,[132],"Dyspnea (i.e. breathlessness) and exercise intolerance are common symptoms for patients with interstitial lung disease (ILD), yet it is not known why. It has been suggested that muscle dysfunction may contribute to dyspnea and exercise intolerance in ILD. Our study aims to: i) examine differences in the structure and function of the leg muscles in ILD patients, ii) determine if leg muscle fatigue contributes to dyspnea and exercise limitation in patients with ILD, and iii) determine the effects of breathing extra oxygen on leg muscle fatigue, as well as ability to exercise in ILD patients.",[30,105,405,406,407],"Hypersensitivity Pneumonitis","Scleroderma","Nonspecific Interstitial Pneumonia",{"date":409,"type":41},"2026-05-15",{"date":386,"type":41},{"date":388,"type":22},{"name":390,"class":143},{"id":414,"slug":415,"hasResults":12,"nctId":416,"briefTitle":417,"officialTitle":418,"acronym":4,"eligibilityCriteria":419,"healthyVolunteers":12,"sex":17,"minAge":420,"maxAge":152,"enrollmentInfo":421,"targetDuration":4,"studyType":23,"phases":422,"briefSummary":424,"conditions":425,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":428,"startDateStruct":429,"completionDateStruct":431,"leadSponsor":433,"locationsCount":49},"100560241","phase-1-adscs-therapy-in-patients-with-ctd-ild-100560241","NCT06574581","ADSCs Therapy in Patients With CTD-ILD","Allogenic Adipose Tissue Derived-MSCs Therapy in Patients With Connective Tissue Diseases-associated Interstitial Lung Disease(CTD-ILD): Phase I\u002FIIa Clinical Trial","Inclusion Criteria:\n\n1. Adult subjects aged between 20 and 80 years who meet the diagnostic criteria for connective tissue diseases such as dermatomyositis, polymyositis, scleroderma, systemic lupus erythematosus, rheumatoid arthritis, or Sjogren's syndrome.\n2. Subjects with refractory or progressive fibrotic interstitial lung disease: Subjects have been treated with steroids and potent immunosuppressants for more than 24 months with continued deterioration of lung function or lung lesions on CT scan (defined as a forced vital capacity (FVC) decline of more than 10% from baseline, an FVC decline of 5-10% with a diffusing capacity for carbon monoxide (DLCO) decline of more than 15% from baseline, or enlargement of lung lesions on CT scan) ; Or subjects with rapidly progressive interstitial lung disease: treated with high-dose steroids (above 0.8 mg\u002Fkg\u002Fday) and potent immunosuppressants for more than 3 months with continued deterioration of lung function or lung lesions on CT scan (defined as an FVC decline of more than 5% from baseline, a DLCO decline of more than 10% from baseline, or enlargement of lung lesions on CT scan); subjects with rapidly worsening condition: Onset of pulmonary symptoms within one month, gradual worsening of dyspnea and decreased blood oxygen levels, or enlargement of lung lesions.\n3. Subjects must have a well-established family support system confirmed by interviews with the principal investigator and social worker.\n4. Negative high-sensitivity urine pregnancy test before the trial.\n5. Agree to use effective contraceptive measures during the trial (e.g., taking contraceptive pills or using intrauterine devices one month before the trial).\n\nExclusion Criteria:\n\n1. Subjects who are unwilling to sign the informed consent form after detailed explanation by the physician.\n2. Patients younger than 20 or older than 80 years who show improvement in lung function or lung lesions on CT scan after 6 months of treatment with steroids and immunosuppressants.\n3. Women who are pregnant or breastfeeding, and women of childbearing age who do not use contraception.\n4. Subjects with abnormal liver function (serum GOT and GPT levels more than twice the upper limit of 40 units, except those caused by inflammatory myopathy) or poor kidney function (serum creatinine levels exceeding 1.4 units).\n5. Subjects with immune deficiencies such as HIV\u002FAIDS or other specific conditions (e.g., those diagnosed with notifiable infectious diseases as per Ministry of Health announcements).","20 Years",{"count":130,"type":22},[423,102],"PHASE1","Connective tissue disease (CTD), an autoimmune and inflammatory disease, usually accompanied by lung interstitial\u002Falveolar inflammation and fibrosis (so called interstitial lung disease, ILD). The prevalence and mortality rate of CTD-ILD increase in recent several years. Although the use of corticosteroids and strong immunosuppressants can improve ILD in some patients with CTD, progressive lung fibrosis which needs lung transplantation and results in respiratory failure, even with mortality is observed. Currently, stem cell therapy is a breakthrough in the treatment of CTD-ILD, and the effective therapy with stem cells for patients with ILD have been reported.",[426,30],"Connective Tissue Diseases","2026-05-11",{"date":382,"type":41},{"date":430,"type":41},"2024-08-20",{"date":432,"type":22},"2027-11-30",{"name":434,"class":143},"China Medical University Hospital",{"id":436,"slug":437,"hasResults":12,"nctId":438,"briefTitle":439,"officialTitle":440,"acronym":4,"eligibilityCriteria":441,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":442,"targetDuration":4,"studyType":23,"phases":443,"briefSummary":444,"conditions":445,"keywords":446,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":447,"lastUpdatePostDateStruct":448,"startDateStruct":449,"completionDateStruct":451,"leadSponsor":453,"locationsCount":4},"100557162","phase-1-human-umbilical-cord-mesenchymal-stem-cell-injection-for-the-treatment-of-interstitial-lung-disease-100557162","NCT06534528","Human Umbilical Cord Mesenchymal Stem Cell Injection for the Treatment of Interstitial Lung Disease","An Open Clinical Study Exploring the Safety, Tolerability, and Preliminary Efficacy of Human Umbilical Cord Mesenchymal Stem Cell Injection in the Treatment of Interstitial Lung Disease (ILD)","Inclusion Criteria:\n\n* Gender not limited, age ≥ 18 years old (including threshold);\n* Clinical diagnosis of interstitial lung disease;\n* Blood biochemistry tests must meet the following criteria: alanine aminotransferase (ALT) ≤ 2.5 × ULN, aspartate aminotransferase (AST) ≤ 2.5 × ULN, total bilirubin (TBIL) ≤ 2 × ULN, direct bilirubin (DBIL) ≤ 1.5 × ULN, or creatinine (Cr) ≤ 3 × ULN;\n* The diffusion capacity of carbon monoxide (DLCO) (corrected by Hb) in lung function tests within the previous 3 months is 30% to 80% of the expected value (including 30% and 80%); Forced vital capacity (FVC) is 40% to 70% of the estimated value (including 40% and 70%)\n\nExclusion Criteria:\n\n* Within the first 3 days of enrollment, use high-dose corticosteroids (equivalent to methylprednisolone\\>240 mg\u002Fday) or irregularly use systemic corticosteroids;\n* For patients receiving immunosuppressive therapy, unstable background treatment with cyclophosphamide, mycophenolate mofetil\u002Fsodium, methotrexate, or other immunosuppressive monotherapy is not allowed (combination therapy is not allowed)\n* Diagnose IPF patients who have previously taken drugs that may cause or worsen pulmonary fibrosis;\n* Individuals with a history of mechanical ventilation or concurrent infectious pneumonia or asthma within the previous month prior to screening; Patients with airway obstruction disease (FEV1\u002FFVC\\\u003C0.7 before using bronchodilators); Patients with other clinically significant serious abnormalities in the lungs; Currently requiring oxygen therapy treatment (oxygen therapy time\\>15h\u002Fd);\n* Pregnant and lactating women\n* Screening for malignant tumors that have occurred within the past 5 years, excluding cervical carcinoma in situ, squamous cell carcinoma of the skin, or basal cell carcinoma that have been previously treated for curative purposes;\n* Individuals who have been hospitalized for 3 or more times due to acute exacerbation of ILD or other respiratory diseases within the past year prior to screening\n* There is evidence that subjects currently have digestive system, urinary system, cardio cerebrovascular, blood system, nervous system, mental and metabolic diseases that may affect safety, such as type 2 diabetes with poor blood sugar control, hypertension with poor blood pressure control, etc\n* have a history of abuse or drug use of psychotropic substances\n* individuals allergic to human serum albumin, anesthetics, or their components\n* Select participants who have participated in any other clinical trials within the previous 3 months;\n* individuals who have previously received stem cell therapy\n* Researchers have determined that the expected survival period may be less than 1 year;\n* Subjects who cannot tolerate bronchoscopy examination (including but not limited to: active massive hemoptysis; severe hypertension and arrhythmia;",{"count":248,"type":22},[423],"Main objective: To explore the safety and tolerability of human umbilical cord mesenchymal stem cell injection in the treatment of interstitial lung disease (ILD); Secondary objective: To explore the preliminary effectiveness of human umbilical cord mesenchymal stem cell therapy for interstitial lung disease (ILD) and recommend appropriate cell therapy doses for subsequent clinical studies; Exploring the immunogenicity of human umbilical cord mesenchymal stem cell injection in the treatment of interstitial lung disease (ILD).",[30],[30,66],"2026-05-06",{"date":427,"type":41},{"date":450,"type":22},"2026-10-01",{"date":452,"type":22},"2027-10-01",{"name":454,"class":76},"Shanghai Life Science & Technology",{"id":456,"slug":457,"hasResults":12,"nctId":458,"briefTitle":459,"officialTitle":460,"acronym":461,"eligibilityCriteria":462,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":152,"enrollmentInfo":463,"targetDuration":4,"studyType":156,"phases":4,"briefSummary":465,"conditions":466,"keywords":475,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":477,"lastUpdatePostDateStruct":478,"startDateStruct":479,"completionDateStruct":481,"leadSponsor":483,"locationsCount":49},"100565589","p4o2-ild-extension-100565589","NCT06644144","P4O2 ILD Extension","Early Identification of Progressive Pulmonary Fibrosis, Precision Medicine for More Oxygen - ILD Extension.","P4O2-ILD","Inclusion Criteria:\n\n* Diagnosis of (1) idiopathic pulmonary fibrosis (IPF), familial pulmonary fibrosis (FPF), (2) other fibrotic ILDs (fILD), including fibrotic hypersensitivity pneumonitis (fHP), idiopathic non-specific interstitial pneumonia (iNSIP), connective tissue disease (CTD)-ILD, and unclassifiable ILD (uILD); or (3) interstitial lung abnormalities (ILA).\n* Meeting all the following criteria during the screening period:\n\n  1. FVC ≥45% predicted.\n  2. FEV1\u002FFVC ≥0.7.\n  3. DLco corrected for Hb ≥40% predicted.\n* Able to provide written informed consent as approved by the independent ethics committee.\n* Able to undergo a CT scan and perform PFT.\n* Age \\> 18 years and \\< 80 years.\n* Understanding of the Dutch or English language.\n\nExclusion Criteria:\n\n* Combined pulmonary fibrosis and emphysema (CPFE) diagnosis\n* Chronic obstructive lung disease (COPD) with an FEV1\u002FFVC \\<70%.\n* Uncontrolled severe asthma.\n* Active malignancy, except for squamous cell carcinoma of the skin, low-risk breast cancer, and low-risk prostate cancer.\n* Pregnancy or lactating.",{"count":464,"type":22},450,"The goal of this observational study is to identify early biomarkers that can predict the development of progressive pulmonary fibrosis (PPF) in participants with interstitial lung diseases (ILDs). The participant population includes adults diagnosed with idiopathic pulmonary fibrosis (IPF), familial pulmonary fibrosis (FPF), other fibrotic ILDs, and interstitial lung abnormalities (ILA).\n\nThe main questions it aims to answer are:\n\n* What biomarkers and risk factors are linked to fibrosis progression or can predict rapid worsening and sudden flare-ups in IPF and FPF patients?\n* What biomarkers and risk factors can predict the development of a PPF phenotype in different types of ILD?\n* What biomarkers and risk factors can help identify ILA patients who may develop significant ILD?\n* What biomarkers and risk factors can predict how well ILD patients will respond to treatment?\n\nResearchers will compare the outcomes between participants diagnosed with IPF\u002FFPF, other fibrotic ILDs, and ILA to see if early detection biomarkers differ among these groups.\n\nParticipants will:\n\n* Undergo blood sampling.\n* Perform lung function tests.\n* Have CT scans.\n* Perform breath analysis\n* Participate in exposome and microbiome analyses.\n* Complete questionnaires.\n* A subgroup of participants will be offered bronchoscopy.",[30,108,467,468,469,470,471,472,473,474],"Interstitial Lung Fibrosis","IPF","Pulmonary Fibrosis, Idiopathic","Pulmonary Fibrosis Idiopathic Familial","Chronic Hypersensitivity Pneumonitis","Unclassifiable ILD","Idiopathic NSIP","CTD-ILD",[30,476,62],"Interstitial Lung Abnormalities","2026-05-05",{"date":427,"type":41},{"date":480,"type":41},"2024-11-01",{"date":482,"type":22},"2031-10-01",{"name":484,"class":143},"Amsterdam UMC, location VUmc",{"id":486,"slug":487,"hasResults":12,"nctId":488,"briefTitle":489,"officialTitle":490,"acronym":4,"eligibilityCriteria":491,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":152,"enrollmentInfo":492,"targetDuration":4,"studyType":23,"phases":493,"briefSummary":494,"conditions":495,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":497,"startDateStruct":499,"completionDateStruct":501,"leadSponsor":503,"locationsCount":49},"100636953","phase-2-advanced-imaging-to-assess-the-effect-of-immunosuppression-on-progressive-fibrosis-100636953","NCT07572383","Advanced Imaging to Assess the Effect of Immunosuppression on Progressive Fibrosis","Advanced Imaging to Assess the Effect of Immunosuppression on Progressive Lung Fibrosis in Participants With Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Disease","Inclusion Criteria:\n\n1. Age 18-80 with a diagnosis of chronic hypersensitivity pneumonitis, connective tissue-associated ILD (due to rheumatoid arthritis, systemic sclerosis, mixed connective tissue disease), or undifferentiated ILD.\n2. Starting immunosuppression treatment with mycophenolate mofetil, mycophenolate sodium, and \u002F or prednisone for clinically indicated non-IPF ILD treatment.\n3. Pulmonary fibrosis, defined as honeycombing, traction bronchiectasis, or reticular opacities on high-resolution computed tomography (HRCT) performed within 1 year to or at Visit 1.\n4. Forced vital capacity (FVC) of \\>\u002F= 45% and diffusing capacity of the lungs for carbon monoxide (DLCO) \\>\u002F= 25% predicted on PFTs performed at Visit 1.\n\nExclusion criteria:\n\n1. Current or prior exposure to FDA approved anti-fibrotic therapy.\n2. Extent of emphysema greater than extent of fibrosis.\n3. Pregnancy or plans to become pregnant at baseline or during follow-up.\n4. Contraindications to MRI.\n5. Contraindications to receiving gadolinium-based contrast agents.\n6. Research-related radiation exposure exceeds 50 millisievert (mSv) in the prior year.\n7. Estimated glomerular filtration rate (eGFR) \\\u003C 30 mL\u002Fmin (only for individuals with a history of chronic kidney disease).\n8. Clinically significant pulmonary hypertension (PH) defined by use of pulmonary vasodilatory therapy.\n9. Respiratory infection within the prior 6 weeks.\n10. Smoking of any kind within the prior 6 months.",{"count":375,"type":22},[102],"The purpose of this study is to investigate how immunosuppression treatment affects measurements of active collagen deposition using \\[68Ga\\]CBP8 positron emission tomography (PET) and tissue injury using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in individuals with non-idiopathic pulmonary fibrosis interstitial lung disease (non-IPF ILD).",[30,108],"2026-05-02",{"date":498,"type":41},"2026-05-07",{"date":500,"type":22},"2026-04",{"date":502,"type":22},"2028-12-31",{"name":504,"class":143},"Peter Caravan",{"id":506,"slug":507,"hasResults":12,"nctId":508,"briefTitle":509,"officialTitle":509,"acronym":4,"eligibilityCriteria":510,"healthyVolunteers":127,"sex":17,"minAge":511,"maxAge":4,"enrollmentInfo":512,"targetDuration":4,"studyType":23,"phases":514,"briefSummary":515,"conditions":516,"keywords":522,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":524,"lastUpdatePostDateStruct":525,"startDateStruct":526,"completionDateStruct":528,"leadSponsor":530,"locationsCount":49},"100410437","phase-1-hyperpolarized-129xe-mr-imaging-of-lung-function-in-healthy-volunteers-and-subjects-with-pulmonary-disease-100410437","NCT04624490","Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease","Inclusion Criteria:\n\nHealthy Volunteers:\n\n* Subject has no diagnosed pulmonary conditions\n* Ability to read and understand English or Spanish\n\nSubjects with Lung Disease:\n\n* Subject has a diagnosis of pulmonary dysfunction made by a physician\n* No acute worsening of pulmonary function in the past 30 days\n* Ability to read and understand English or Spanish\n\nExclusion Criteria:\n\n* MRI is contraindicated based on responses to MRI screening questionnaire\n* Subject is pregnant or lactating\n* Subject does not fit into 129Xe vest coil used for MRI\n* Subject cannot hold his\u002Fher breath for 15-16 seconds\n* Subject deemed unlikely to be able to comply with instructions during imaging\n* Oxygen saturation \\\u003C88% on room air or with supplemental oxygen\n* Cognitive deficits that preclude ability to provide consent\n* Institutionalization","3 Years",{"count":513,"type":22},260,[423],"The purpose of this study is to develop and evaluate the usefulness of hyperpolarized (HP) 129Xe gas MRI for regional assessment of pulmonary function.",[517,518,30,519,159,520,521],"Asthma","COPD","Cystic Fibrosis","Pulmonary Infection","Other Lung Disease",[523],"Hyperpolarized 129Xe MRI","2026-04-30",{"date":447,"type":41},{"date":527,"type":41},"2020-11-02",{"date":529,"type":22},"2028-10-26",{"name":531,"class":143},"Mario Castro, MD, MPH",{"id":533,"slug":534,"hasResults":12,"nctId":535,"briefTitle":536,"officialTitle":536,"acronym":537,"eligibilityCriteria":538,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":539,"targetDuration":4,"studyType":156,"phases":4,"briefSummary":541,"conditions":542,"keywords":546,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":548,"lastUpdatePostDateStruct":549,"startDateStruct":550,"completionDateStruct":552,"leadSponsor":554,"locationsCount":49},"100534193","detection-of-rheumatoid-arthritis---interstitial-lung-disease-by-thoracic-ultrasound-100534193","NCT06235645","dEtection of rheumAtoid aRthritis - Interstitial Lung dIseasE by Thoracic ultRasound","EARLIER","Inclusion Criteria:\n\n* Adult patient (age \\> 18 years) followed at CHU of Tours\n* Diagnosis of rheumatoid arthritis validated according to ACR 2010 criteria, EULAR classification, regardless of time since diagnosis\n* Patient who has had or will have a thoracic CT scan and PFT performed as part of routine care in the 6 months preceding or following inclusion\n* Patient with at least two risk factors for developing RA-ILD among :\n\n  * Male sex or\n  * Active or former smoker assessed at 20 pack-year or\n  * Age \\> 60 years or\n  * Levels of RF≥3N (rheumatoid factor) and\u002For anti-CCP≥3N (antibodies against cyclic citrullinated peptides) at diagnosis or at any time during the course of the disease or\n  * High RA activity score (DAS28\\>3.2)\n\nExclusion Criteria:\n\n* Diagnosis of congenital lung disease\n* Diagnosis of another autoimmune pathology associated with RA (overlap syndrome) linked to the development of ILD (interstitial lung disease) (systemic sclerosis, myositis, dermatomyositis, mixed connectivitis, systemic lupus erythematosus or other ANCA vasculitis, with the exception of secondary Gougerot-Sjögren's syndromes).\n* Current or operated lung cancer\n* Thoracic irradiation\n* Thoracic transplant patients\n* Previous invasive thoracic procedures\n* Pathologies responsible for pleural thickening (silicosis, asbestosis, known pleural plaque, pleural sequelae of tuberculosis)\n* Pregnant or breast-feeding women\n* Patient under legal protection (guardianship, curatorship or safeguard of justice)\n* Patient who has objected to data processing\n* Parenchymal infection current or less than one month old prior to LUS examination\n* Liquid or gaseous pleural effusion",{"count":540,"type":22},280,"Rheumatoid arthritis is an autoimmune disease that can affect various organs, including the lungs, and lead to rheumatoid arthritis-interstitial lung disease (RA-ILD).\n\nRA-ILD is responsible for increased mortality in rheumatoid arthristis (RA) patients.\n\nThe prevalence of RA-ILD varies according to the screening tool used.\n\nThe current gold standard is chest CT, but this is an expensive, time-consuming and irradiating examination, and recommendations on when and how often it should be performed are not clearly established.\n\nLung ultrasound (LUS) is an emerging tool for the detection of lung parenchymal damage, particularly in systemic scleroderma and idiopathic pulmonary fibrosis (IPF).\n\nLUS is a non-irradiating, non-expensive examination that can be performed rapidly.\n\nThe aim of our study is to evaluate LUS as a screening tool for RA-ILD, in patients with risk factors for developing RA-ILD.",[543,30,544,545],"Rheumatoid Arthritis","Thoracic Ultrasound","Lung Ultrasound",[547,543,30],"Lung ultrasound","2026-04-29",{"date":524,"type":41},{"date":551,"type":41},"2024-11-18",{"date":553,"type":22},"2027-03",{"name":555,"class":143},"University Hospital, Tours",{"id":557,"slug":558,"hasResults":12,"nctId":559,"briefTitle":560,"officialTitle":560,"acronym":561,"eligibilityCriteria":562,"healthyVolunteers":12,"sex":17,"minAge":563,"maxAge":564,"enrollmentInfo":565,"targetDuration":567,"studyType":156,"phases":4,"briefSummary":568,"conditions":569,"keywords":570,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":577,"lastUpdatePostDateStruct":578,"startDateStruct":580,"completionDateStruct":582,"leadSponsor":584,"locationsCount":49},"100308627","rheumatoid-arthritis-patients-at-risk-for-interstitial-lung-disease-100308627","NCT03297775","Rheumatoid Arthritis Patients at Risk for Interstitial Lung Disease","RAPID","Inclusion Criteria:\n\n1. ≥ 45years old\n2. Diagnosis of RA using the 2010 American College of Rheumatology (ACR) criteria\n\nExclusion Criteria:\n\n1. Inability to give informed consent\n2. Pregnant women\n3. History of interstitial lung disease\n4. Evidence of other causes of diffuse parenchymal lung disease such as infection, drug toxicity, other autoimmune processes, etc.\n5. Subjects over the age of 90 years old or less than 45 years old","45 Years","90 Years",{"count":566,"type":22},750,"5 Years","The overall goal of this study is to define the phenotype of Interstitial Lung Disease (ILD), and identify factors that predict radiologic progression in those with subclinical RA-ILD, in patients with rheumatoid arthritis (RA). The investigators hypothesize that there are common core elements (e.g. clinical features, genetic variants, and\u002For biologic markers) between other forms of ILD (e.g. idiopathic pulmonary fibrosis, IPF) and subclinical RA-ILD that places individuals at risk for the development of lung disease.",[543,30],[543,571,30,66,572,573,574,575,468,576],"RA","lung disease","connective tissue disease","CTD","idiopathic pulmonary fibrosis","airways disease","2026-04-27",{"date":579,"type":41},"2026-05-01",{"date":581,"type":41},"2017-06-22",{"date":583,"type":22},"2027-06",{"name":585,"class":143},"University of Colorado, Denver",{"id":587,"slug":588,"hasResults":12,"nctId":589,"briefTitle":590,"officialTitle":590,"acronym":4,"eligibilityCriteria":591,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":592,"targetDuration":4,"studyType":23,"phases":594,"briefSummary":595,"conditions":596,"keywords":597,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":601,"lastUpdatePostDateStruct":602,"startDateStruct":603,"completionDateStruct":605,"leadSponsor":607,"locationsCount":4},"100636080","the-benefits-of-home-exercise-in-pulmonary-hypertension-interstitial-lung-disease-100636080","NCT07561034","The Benefits of Home Exercise in Pulmonary Hypertension Interstitial Lung Disease","Inclusion Criteria:\n\n* Follows at University of Rochester Medical Center Pulmonary Hypertension Clinic.\n* Adult patients (\\>18 years old) with right heart catheterization confirmed pulmonary hypertension interstitial lung disease on stable therapy dosing for at least 30 days.\n* Access to a smart phone or email to receive daily messages.\n* Clinically stable by the investigator.\n\nExclusion Criteria:\n\n* Pregnancy.\n* Pulmonary Hypertension Groups 1,2,4,5.\n* Resting tachycardia \\>120 beats\u002Fm during screening.\n* Inability to walk.\n* WHO Functional Class IV\n* Lack of access to email or text messaging.\n* Participating in a rehabilitation program.",{"count":593,"type":22},30,[132],"This study evaluates the effects of a structured home exercise program in participants with pulmonary hypertension associated with interstitial lung disease. Participants will complete a defined exercise regimen over a 16-week period, and functional capacity and patient reported outcomes will be assessed at baseline and after the intervention. The study aims to determine whether a home-based exercise approach is feasible and associated with improvements in functional performance.",[159,30],[598,599,600],"Home Exercise","Exercise Therapy","PH-ILD","2026-04-24",{"date":579,"type":41},{"date":604,"type":22},"2026-05-30",{"date":606,"type":22},"2027-05-30",{"name":608,"class":143},"University of Rochester",{"id":610,"slug":611,"hasResults":12,"nctId":612,"briefTitle":613,"officialTitle":613,"acronym":4,"eligibilityCriteria":614,"healthyVolunteers":127,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":615,"targetDuration":4,"studyType":156,"phases":4,"briefSummary":617,"conditions":618,"keywords":619,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":601,"lastUpdatePostDateStruct":620,"startDateStruct":621,"completionDateStruct":623,"leadSponsor":625,"locationsCount":49},"100322509","creation-of-a-biospecimen-repository-from-patients-with-interstitial-lung-diseases-ild-100322509","NCT03478826","Creation of a Biospecimen Repository From Patients With Interstitial Lung Diseases (ILD)","Inclusion Criteria:\n\n* Patients with a diagnosis of ILD or any fibrotic disease of the lung or a diagnosis of pneumonia\n* Patients willing to provide written informed consent\n\nExclusion Criteria:\n\n* Unwillingness\u002Funable to give blood samples",{"count":616,"type":22},635,"To develop a repository of blood samples from patients with ILD to support future studies into the development of such biomarkers. Patients with pneumonia and healthy patients will also be recruited as a control group.",[30],[66],{"date":548,"type":41},{"date":622,"type":41},"2018-08-01",{"date":624,"type":22},"2028-01",{"name":626,"class":143},"Mayo Clinic"]